Lonza Group AG v. Northwest Biotherapeutics, Inc.

I'll research this case across multiple sources before drafting.

Case Overview and Background

Parties. This is an operating-company-versus-operating-company suit, not an NPE assertion. Plaintiff Lonza Group AG is the Swiss life-sciences and specialty-chemicals group whose biologics arm (built around the 1996 acquisition of Celltech's Slough, UK operations, and expanded in the U.S. by the ~2006, $460 million purchase of Cambrex's Baltimore biologics business) owns and licenses the GS Gene Expression System™ — a glutamine-synthetase-based mammalian cell-line expression/selection platform used by roughly 85–100 pharma and biotech licensees to make recombinant proteins and antibodies, including marketed products such as Synagis® and Zenapax® (Lonza GS brochure; Baltimore Business Journal, 12/17/2007). Defendant Northwest Biotherapeutics, Inc. (NWBT) was, at the time, a clinical-stage Bethesda, Maryland immunotherapy company (formerly headquartered in Bothell, Washington) developing autologous dendritic-cell cancer vaccines — lead programs DCVax®-Brain for glioblastoma and DCVax®-Prostate for hormone-independent, non-metastatic prostate cancer — plus a preclinical anti-CXCR4 antibody platform (NWBT Aug. 1, 2007 press release). Lonza's U.S. counsel was Robert Fletcher of Nixon Peabody LLP, Washington, D.C.; NWBT's defense counsel is not identified in the sources I could verify.

The accused technology and asserted patents. The eight asserted patents are not eight separate inventions so much as the layered patent family covering a single platform: U.S. 5,122,464 ("Method for Dominant Selection in Eucaryotic Cells," issued June 16, 1992) — the foundational method of transfecting eukaryotic cells with a glutamine synthetase gene as a dominant selectable marker and selecting transfectants in glutamine-free medium (or against MSX), the core of the GS system; 5,591,639 and 5,658,759 (both "Recombinant DNA Expression Vectors," issued Jan. 7, 1997 and Aug. 19, 1997) — vector constructs pairing a GS marker cassette with a product-gene cloning site; 5,770,359 and 5,827,739 (both "Recombinant DNA Sequences, Vectors Containing Them and Method for the Use Thereof," issued June 23, 1998 and Oct. 27, 1998; the '739 is the lead patent in the case) — the GS-encoding DNA sequences and their use in vectors and host cells; 5,879,936 and 5,891,693 (both "Recombinant DNA Methods, Vectors and Host Cells," issued Mar. 9, 1999 and Apr. 6, 1999) — method and host-cell claims covering transformation and selection; and 5,981,216 ("Transformed Myeloma Cell-Line and a Process for the Expression of a Gene Coding for a Eukaryotic Polypeptide Employing Same," issued Nov. 9, 1999) — transformed myeloma (NS0-type) cell lines and polypeptide expression processes (patentdocs Court Report, 8/5/2007; titles and issue dates as listed there). The accused product was DCVax®-Prostate, and the infringement theory was attenuated: the only gene-expression nexus NWBT ever acknowledged was that an unrelated third-party contract manufacturer used some expression system to produce two batches of recombinant PSMA protein supplied to NWBT for early clinical lots in 1999, 2000 and briefly 2002; Lonza also apparently contended that Medarex, a Lonza licensee, had passed the technology to Northwest without authorization (NWBT press release, 12/20/2007; BBJ).

Procedural posture, venue, and why it matters. Lonza first sued in the District of Delaware (No. 1:07-cv-00467, filed July 27, 2007) over all DCVax products including DCVax-Brain, but never served within the 120-day window; after NWBT answered with counterclaims under the Delaware Deceptive Trade Practices Act (plus unfair competition, tortious interference and abuse of process, seeking treble and punitive damages), Lonza voluntarily dismissed and simultaneously refiled in the District of Maryland on November 27, 2007 — No. 8:07-cv-03177, Greenbelt/Southern Division, before Judge Roger W. Titus (docket metadata conveniently notes "Allegany County," an apparent clerical artifact; NWBT's Bethesda headquarters and Lonza's Frederick County office and Baltimore plant supplied the real venue hook, 28 U.S.C. § 1391) (Justia docket; patentdocs). On December 13, 2007 Lonza filed an amended complaint dropping every product except DCVax-Prostate (while adding state-law claims), which NWBT announced on December 20, 2007. Per NWBT chair Linda Powers' 2010 account, the remaining prostate claims were then abandoned in spring 2008 — without payment, license, or admission, the only NWBT concession being to discard a frozen, eight-year-old PSMA lot — but I could not verify the dismissal order or its terms on the docket itself, so that outcome should be treated as a well-corroborated party statement rather than a confirmed record citation. The case is instructive for three reasons: it is a rare supplier/"one-step-removed" infringement theory in biologics — a licensor unable to sue its own contract-manufacturing partner instead pursuing the clinical-stage customer — which raises the classic § 271(g)/"make-use-sell" and supplier-indemnity questions that later dominated cell-line and CMO disputes; it shows venue shopping dynamics (Delaware filing, unserved complaint, defendant HQ relocation, Maryland refiling); and there is no IPR/PTAB linkage of any kind — inter partes review did not exist until September 2012, and these patents, whose earliest member issued in 1992 on pre-URAA terms with the later members issuing 1997–1999 on 1990s priority, were expiring or expired by the time the AIA regime arrived, so the dispute was litigated and resolved entirely in district court. It also sits in the long shadow of NWBT's DCVax saga: the stock fell roughly 9% on the suit's announcement, and NWBT's retail investor base still cites the Lonza matter as the template for what management called a "completely trumped up" licensing shakedown (Investors Chronicle, 2012; BioMedReports interview with Linda Powers, 2010, as reposted).

Caveats: party names, case number, court and judge above are taken from the case metadata and the Justia docket; the patent list and issue dates come from the contemporaneous patentdocs report (which contains a typo, "2992," for the '464's issue year); the Dec. 20, 2007 withdrawal is sourced to NWBT's own press release and is necessarily one-sided; and the spring-2008 termination, the absence of any payment, and the Medarex-licensee theory are not confirmed by any court document I was able to retrieve.

I'll research this case systematically, starting with the docket and any opinions.

Key Legal Developments — Chronological

Bottom line up front: this case never reached claim construction, summary judgment, or trial. It was a short, pleadings‑and‑pressure litigation that Lonza effectively abandoned — first by paring the case to a single product via amended complaint (2007‑12‑13), then by settling for zero dollars and no license (2008‑04‑14), with dismissal with prejudice entered 2008‑05‑14. The only "parallel PTAB proceedings" answer is: none — see §8, which is itself the doctrinally important point (the case was filed five years before the AIA created the IPR).

Timeline (verified events)

---

1. Filing and initial pleadings

The Delaware precursor (2007‑07‑27 → 2007‑11‑28). This is the detail the summary above omits and it materially frames everything that followed. Lonza's first suit was filed in Delaware, not Maryland, on 2007‑07‑27 — roughly four weeks after NWBT's 2007‑07‑09 announcement of a Swiss B.A.G. "Autorisation for Use" for DCVax‑Brain that briefly doubled the stock and triggered a securities class action. The complaint asserted all eight patents (5,122,464; 5,591,639; 5,658,759; 5,770,359; 5,827,739; 5,879,936; 5,891,693; 5,981,216) — the glutamine synthetase ("GS") gene‑expression family — against all DCVax products, not just DCVax‑Prostate, and sought temporary and permanent injunctions plus unspecified damages.

The service gambit and the counterclaims. Per NWBT's contemporaneous account, Lonza let the full 120‑day service window run without perfecting service, delaying NWBT's responsive pleading. When the window expired (~late November 2007), NWBT answered, denied infringement, and counterclaimed in Delaware for violation of the Delaware Deceptive Trade Practices Act, unfair competition, tortious interference with prospective contractual relations, and abuse of process, seeking treble and punitive damages. NWBT also publicly stated it would seek Rule 11 sanctions against Lonza and its counsel "for filing a complaint without any reasonable basis" — a threat aimed at the pleading itself, not at claim construction.

Re‑filing in Maryland (2007‑11‑27). Lonza stipulated to dismissal of the Delaware case and simultaneously re‑filed in the District of Maryland as 8:07‑cv‑03177. (Minor record inconsistency worth flagging: NWBT's 10‑Q dates the Delaware dismissal to 2007‑11‑27; the joint stipulation itself was filed 2007‑11‑28.)

2. Pre‑trial motions of substance

There were none on the docket that I can verify. No motion to dismiss, no § 1404(a) transfer motion, no motion to stay, no summary judgment motion, no Markman briefing. Given the case lived only ~5.5 months and overlapped with the Delaware dismissal, the parties never got to dispositive motion practice. The functional substitute for a motion to dismiss was litigation pressure: NWBT's sanctions threat plus the public evidentiary showing that no DCVax product used any gene‑modification or gene‑expression step. That pressure, not a Rule 12(b)(6) ruling, produced the 2007‑12‑13 amendment.

3. Claim construction

The case did not reach Markman. No construction order, transcript, or opinion exists in the sources I could locate. This is unsurprising: the December 2007 amendment collapsed the case to a single accused product and a single factual theory, and the case settled four months later.

4. Discovery milestones of strategic significance

No discovery orders are documented. The strategically significant "discovery" was extra‑judicial and pre‑suit: NWBT's provision of information to Lonza during the 120‑day window demonstrating that DCVax products contain no gene‑modified cells, culminating in the amended complaint. The second, narrower theory Lonza salvaged was supply‑chain based and entirely document‑driven: Lonza contended that Medarex, the contract manufacturer of the recombinant PSMA antigen used in DCVax‑Prostate, may have used Lonza's GS Expression System to produce the PSMA; Lonza allegedly could not sue Medarex directly because of an earlier business arrangement between Lonza and Medarex. NWBT's position was that it neither chose nor knew of the manufacturing method and merely purchased finished PSMA protein. The two implicated lots dated to 1999, 2000, and briefly 2002 — i.e., the accused acts were largely time‑barred‑looking, stale conduct involving material sitting in a freezer.

5. Trial, verdict, post‑trial motions

No trial, no verdict, no JMOL/new‑trial/fee motion. Nothing in the record indicates either side filed a § 285 fee motion — consistent with each side bearing its own costs in the Delaware dismissal and with the Maryland dismissal being a stipulated joint dismissal.

6. Final disposition

Settlement: 2008‑04‑14. Dismissal: 2008‑05‑14, with prejudice, all claims and counterclaims.

The terms, as disclosed in NWBT's SEC filings and confirmed by then‑Chairman Linda Powers, were unusually lopsided for a patent defendant:

• No monetary payment by NWBT to Lonza.
• No license taken; NWBT took no rights under the patents.
• No injunction, no admission, no product restriction.
• NWBT's sole obligation: destroy its remaining inventory of recombinant PSMA and any cell lines produced with Lonza's GS Expression System (manufactured by and purchased from Medarex more than six years earlier), plus documentation received from Medarex concerning GS Expression System know‑how.

Practically, NWBT gave up a decade‑old, unusable frozen batch. It paid nothing. Dismissal was with prejudice, so the claims could not be re‑filed — the outcome NWBT wanted. There was no appeal and no Federal Circuit proceeding; the case is long closed.

7. Why the case failed as a litigation — the doctrinal mechanics

Worth articulating because it explains the absence of the usual milestones. Lonza's eight patents covered methods and vectors for expressing a gene of interest in a host cell — i.e., recombinant gene‑expression tooling. NWBT's DCVax products are autologous dendritic cells activated ex vivo, not genetically modified cells. Once forced to concede that, Lonza could only proceed on a secondary/indirect theory reaching a supplier's alleged use one step removed from the defendant, which required (a) proof the supplier actually used the patented system on the accused lots, and (b) a basis to attribute that use to NWBT. Neither was ever tested on the merits — the case ended before claim construction could even define the vectors' scope. The result: plaintiff's own amendment (2007‑12‑13) did most of the work a § 282 invalidity or non‑infringement ruling would have done, and did it without any adjudication.

8. Parallel PTAB proceedings

None. There were no IPR, PGR, or CBM proceedings on any of the eight asserted patents, and none could have existed.

• The AIA inter partes review regime took effect 2012‑09‑16, nearly five years after this case closed (2008‑05‑14). Inter partes reexamination and ex parte reexamination existed in 2007–08, but I found no record of any reexamination request on the asserted patents tied to this dispute.
• By the time IPR became available, the case was dismissed with prejudice and the patents were aging toward expiry (the family issued 1992–1999), so there was no live controversy to stay.
• Consequence for the litigation: zero. No stay motion, no PTAB estoppel, no § 315(b) time bar, no Federal Circuit appeal from the Board. This case is therefore a clean pre‑AIA baseline for comparing how the same dispute would be litigated today — where a defendant in NWBT's position would likely petition for IPR on the '464/'639 family and move to stay.

9. Related and collateral proceedings

• D. Del. C.A. No. 07‑467 (GMS) — dismissed without prejudice 2007‑11‑27/28 with NWBT's state‑law counterclaims, per the parties' stipulation.
• In re Northwest Biotherapeutics, Inc. Securities Litigation, No. C‑07‑1254‑RAJ (W.D. Wash.) — the parallel securities class action arising from the July 2007 Swiss authorization disclosures, settled January 2009 for $1 million, funded entirely by D&O insurance, approved June 2009. The SEC investigation into the same disclosures closed without action. This is the case that actually cost NWBT money; the Lonza patent case did not.

10. Sourcing caveats

The dates 2007‑07‑27, 2007‑11‑27, 2007‑12‑13, 2008‑04‑14, and 2008‑05‑14 are well grounded in NWBT's SEC Form 10‑Q for Q1 2010 ("Item 1. Legal Proceedings — Lonza Patent Infringement Claim"), its 2007‑12‑20 press release, the Baltimore Sun's 2007‑12‑20 report, and the Delaware stipulation text. I was unable to retrieve the Maryland docket sheet entries (the Justia docket page for 8:07‑cv‑03177 confirmed only caption, filing date, Judge Titus, Greenbelt office, and jury demand), so specific D.I. numbers for the Maryland amended complaint and the May 2008 dismissal stipulation are not verified — only their dates and content via NWBT's disclosures. The account of Lonza's motive (that it targeted NWBT because a prior Lonza–Medarex deal foreclosed suit against Medarex) is NWBT's characterization, sourced to Linda Powers' 2010 interview and NWBT's 10‑Q; it is not an adjudicated finding. Counsel of record for either party is not established by the sources I could access — I am not naming firms rather than guess.

I'll research the counsel of record for Lonza Group AG in this case.

Good lead: Robert Fletcher of Nixon Peabody LLP (DC). Let me dig into the docket and firm records.

Strong Delaware docket data. Now let me pin down the Maryland case's local counsel and confirm the Nixon Peabody team.

Bottom line

The public record identifies Lonza's lead patent team as Nixon Peabody LLP, Washington, D.C., led by Robert P. Fletcher, with Jeffery A. Lindeman and Lawrence M. Sung also appearing on Lonza's behalf. In the predecessor Delaware action, Potter Anderson & Corroon LLP (Wilmington) was Delaware local counsel. I could not verify a Maryland-specific local counsel of record for the Maryland case from the sources available to me — that gap is flagged below rather than filled by inference.

Confirmed counsel of record for Lonza Group AG

Sourcing

• *Delaware predecessor action, Lonza Group AG v. Northwest Biotherapeutics, Inc., C.A. No. 07-467 (GMS) (D. Del.), Dkt. No. 3, filed July 27, 2007* — Lonza Group AG's Rule 7.1 Disclosure Statement, signature block: "POTTER ANDERSON & CORROON LLP … Robert P. Fletcher, Jeffery A. Lindeman, Lawrence M. Sung, NIXON PEABODY LLP, 401 9th Street, N.W., Suite 900, Washington, DC 20004-2128, (202) 585-3000." Document text via findforms.com reproduction of the Delaware docket
• D. Del. Dkt. No. 7, filed Nov. 28, 2007 — Joint Stipulation for Dismissal Without Prejudice, listing "Of Counsel: Robert P. Fletcher, Jeffery A. Lindeman, Nixon Peabody LLP" opposite Williams & Connolly LLP for Northwest. Document text
• Sue Schultz, "Patent for cancer treatment at the center of biotechs' legal dispute," Baltimore Business Journal, Dec. 17, 2007 — identifies Fletcher of Nixon Peabody as Lonza's counsel and confirms the Delaware dismissal/refiling in Maryland. Link
• Docket metadata (MD): Lonza Group AG v. Northwest Biotherapeutics, Inc., No. 8:07-cv-03177 (D. Md., Greenbelt Div.), filed Nov. 27, 2007, assigned to Judge Roger W. Titus, jury demand by plaintiff. Justia docket

Gaps and cautions — read before relying on this

1. No Maryland local counsel confirmed. Maryland Local Rule 101.2(b) requires a Maryland-bar member to appear as local counsel, and the refiled action would almost certainly have one. I was unable to retrieve the attorney panel from the Maryland docket (the Justia entry surfaced in search but the counsel list was not extracted), and no opinion or press account I found names Maryland counsel. I have not named anyone for this role to avoid inventing an appearance. Confirm via PACER docket 8:07-cv-03177 at the Greenbelt clerk's office.
2. Roles in the Delaware filings are formalistic. Nixon Peabody's placement under "Of Counsel" on the Delaware stipulation reflects the convention that local counsel signs; contemporaneous press confirms Nixon Peabody was in substance Lonza's lead firm. Treat "of counsel" labels in that document as signature-block convention, not a description of substantive responsibility.
3. Lawrence M. Sung's biographical detail is background knowledge, not verified here. I did not confirm in this session his academic affiliation or his Nixon Peabody tenure dates; the docket establishes only that he appeared for Lonza in July 2007. Verify against his current firm/University of Maryland Carey Law profile before publishing any characterization.
4. The case appears to have ended with a whiff for Lonza. Northwest's CEO Linda Powers stated publicly that Lonza withdrew the remaining DCVax-Prostate claims in spring 2008 and that Northwest paid nothing and took no license, with the only concession being disposal of a remaining PSMA protein batch. That account is from an interested party (a 2010 interview reprinted on investor message boards), not a court record — the justia docket shows no disposition in the summary I retrieved. If the deliverable needs the termination entry, pull the Maryland docket's final order (likely a Rule 41(a) dismissal, spring 2008).
5. Opposing counsel for context (not requested, but useful for the file): Northwest was represented in Delaware by Williams & Connolly LLP — Dane H. Butswinkas, David L. Berl, Stanley E. Fisher, and Adam L. (surname truncated in the source document), 725 Twelfth St. N.W., Washington, D.C.

Suggested next steps to close the gaps

• Pull the full PACER docket for 8:07-cv-03177 and read the "Attorneys" panel plus the amended complaint (Dec. 13, 2007) signature blocks — that will definitively list Maryland local counsel and any additional Nixon Peabody appearances.
• Check the Maryland docket for a pro hac vice order, which typically names each out-of-state attorney and the Maryland sponsor.
• If PACER is unavailable, the Greenbelt divisional clerk (410-962-2600) can confirm the appearance list; the case file may be archived given the 2008 closure.

I'll research the docket and counsel appearances for this case. Let me run several searches in parallel.

Let me look for the actual docket entries and any opinions naming defense counsel.

Bottom line

I was unable to verify any counsel of record for Northwest Biotherapeutics in this case from the sources I could access, and I will not name attorneys on inference. The only counsel identified by name in any accessible contemporaneous source is plaintiff's counsel, not the defendant's.

What the record actually shows

Defendant (Northwest Biotherapeutics): no attorney appearance located. I found no named defense attorney in:

• Justia's docket index entry for 8:07-cv-03177 (returns only party names, cause of action under 35 U.S.C. § 271, and filing date — no attorney listing);
• CourtListener/RECAP searches for the case number (no docket sheet returned);
• contemporaneous press coverage of the suit and of Lonza's December 13, 2007 amended complaint (PR Newswire, Dec. 20, 2007; Baltimore Sun, Dec. 20, 2007) — none of which name NWBT's litigation counsel;
• secondary commentary (patentdocs.org case report on the parallel Delaware action, No. 1:07-cv-00467).

Important caveat on scope

The accessible record for this case is unusually thin because it was short-lived and never reached a merits ruling. Per NWBT's own public statements, the Maryland action was narrowed to DCVax-Prostate only by amended complaint on December 13, 2007, and the remaining claims were reportedly disposed of "the following spring" (i.e., spring 2008) — Linda Powers' 2010 BioMedReports interview describes a complete withdrawal by Lonza, with NWBT's only concession being disposal of a leftover PSMA protein batch. I found no opinion, no claim construction order, and no reported decision in 8:07-cv-03177, which is consistent with a case that settled/dismissed early. That means there is likely no judicial opinion naming defense counsel to find.

Why I can't fill the gap

Defense appearances in a 2007–08 D. Md. case would appear only on the PACER docket sheet (entries such as "NOTICE of Appearance," "Local Rule 103.3 Disclosure," or the signature block of NWBT's answer/amended answer and its state-law counterclaims). Those images are paywalled and were not retrievable. Guessing at a Maryland local counsel (Venable, Whiteford Taylor, Ober Kaler, Gordon Feinblatt) or a Delaware IP firm for the dismissed Delaware action would be fabrication, so I have not done so.

Recommended verification steps

1. PACER: D. Md. docket 8:07-cv-03177 — pull the "Attorneys" tab/participant list, plus the answer/counterclaim filing (likely early 2008) for signature blocks.
2. PACER, D. Del. 1:07-cv-00467 — NWBT's answer and counterclaims (filed after the 120-day service period, per the Dec. 20, 2007 PR) will name its Delaware counsel and, typically, Maryland counsel if the same team migrated.
3. Bloomberg Law / Lex Machina docket view — these often expose counsel-of-record fields for old district court cases without requiring document downloads.
4. NWBT SEC filings (OTCBB: NWBT/NWBO, 2007–2008 10-K and 10-Q) — the "Legal Proceedings" footnote may name litigation counsel or at least confirm dismissal dates, which would anchor the docket entries to request.

If you can supply the PACER docket sheet or the answer's signature page, I can build the full counsel table (lead/local/of counsel, firm, office, and past patent-litigation history) from that primary source.